ArticleJournal of molecular medicine (Berlin, Germany)2018
Genetic ablation of adenosine receptor A3 results in articular cartilage degeneration.
Article in Journal of molecular medicine (Berlin, Germany), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 20 citations in OpenAlex.
- Piclidenoson, an A3 adenosine receptor agonist, demonstrates clinical benefit in canine osteoarthritis: a pilot study.Frontiers in veterinary science · 2026Trial
- Purinergic signaling in osteoarthritis: Mechanistic insights into pathogenesis and therapeutic targeting.Genes & diseases · 2026Review
- A3 Adenosine Receptor Agonists as Multisystem Disease Modifiers: From Molecular Signaling to Clinical Translation.Biomolecules · 2026Review
- Intra-articular injections of liposomal adenosine improve clinical outcomes and slow radiologic progression in a preclinical canine model of osteoarthritis.Osteoarthritis and cartilage open · 2026Article
- Stage-Specific Mechanisms of Manual Acupuncture and Electroacupuncture in Inflammatory Pain: A Time-Dependent Review.Journal of pain research · 2026Review
- Biased agonism of G protein-coupled receptors as a novel strategy for osteoarthritis therapy.Bone research · 2025Review
- Adenosine metabolism and receptors in aging of the skin, musculoskeletal, immune and cardiovascular systems.Ageing research reviews · 2025Review
- The function of GPCRs in different bone cells.International journal of biological sciences · 2025Review
- Stimuli-responsive microcarriers and their application in tissue repair: A review of magnetic and electroactive microcarrier.Bioactive materials · 2024Review
- 2-Substituted (N)-Methanocarba AACS pharmacology & translational science · 2024Article
- Purines and Adenosine Receptors in Osteoarthritis.Biomolecules · 2023Review
- Notch Signaling Regulates the Chondrogenic Potential of Both Articular Chondrocytes and Their Progenitors During Expansion.Stem cells (Dayton, Ohio) · 2023Article
- Activation of adenosine A3 receptor attenuates progression of osteoarthritis through inhibiting the NLRP3/caspase-1/GSDMD induced signalling.Journal of cellular and molecular medicine · 2022Article
- International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update.Pharmacological reviews · 2022Review
- Pulsed Electromagnetic Field Stimulation in Osteogenesis and Chondrogenesis: Signaling Pathways and Therapeutic Implications.International journal of molecular sciences · 2021Review
- G Protein-Coupled Receptors in Osteoarthritis.Frontiers in endocrinology · 2021Review
- Intraarticular injection of liposomal adenosine reduces cartilage damage in established murine and rat models of osteoarthritis.Scientific reports · 2020Article
- Purinergic System Signaling in Metainflammation-Associated Osteoarthritis.Frontiers in medicine · 2020Review
- CD73 (Cluster of Differentiation 73) and the Differences Between Mice and Humans.Arteriosclerosis, thrombosis, and vascular biology · 2019Review
- Signaling of the Purinergic System in the Joint.Frontiers in pharmacology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
Abstract
Osteoarthritis (OA), the most common form of arthritis, is characterized by inflammation of joints and cartilage degradation leading to disability, discomfort, severe pain, inflammation, and stiffness of the joint. It has been shown that adenosine, a purine nucleoside composed of adenine attached to ribofuranose, is enzymatically produced by the human synovium. However, the functional significance of adenosine signaling in homeostasis and pathology of synovial joints remains unclear. Adenosine acts through four cell surface receptors, i.e., A1, A2A, A2B, and A3, and here, we have systematically analyzed mice with a deficiency for A3 receptor as well as pharmacological modulations of this receptor with specific analogs. The data show that adenosine receptor signaling plays an essential role in downregulating catabolic mechanisms resulting in prevention of cartilage degeneration. Ablation of A3 resulted in development of OA in aged mice. Mechanistically, A3 signaling inhibited cellular catabolic processes in chondrocytes including downregulation of Ca KEY MESSAGES: Adenosine receptor A3 (A3) knockout results in progressive loss of articular cartilage in vivo. Ablation of A3 results in activation of matrix degradation and cartilage hypertrophy. A3 agonists downregulate RUNX2 and CaMKII expression in osteoarthritic human articular chondrocytes. A3 prevents articular cartilage matrix degradation induced by inflammation and osmotic fluctuations. A3 agonist inhibits proteolytic activity of cartilage-degrading enzymes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.